image dons

I make a donation

AGENT

Transfer of the Serca2a gene via a AAV1 type vector (adeno-associated viral 1) for treating severe cardiac insufficiency

Terminée

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

logo étude

objectif

Transfer of the Serca2a gene via a AAV1 type vector (adeno-associated viral 1) for treating severe cardiac insufficiency.

date de réalisation

2015

nombre de patients

44

nombre de centres participants

5 french centers

type de financement

Public (APHP) and private (Groupe ACTION & Celladon)

Référence

NCT01966887

AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure (AGENT-HF)

Study Description

The purpose of gene transfer of SERCA2a is to improve systolic and diastolic function of the failing ventricle. Studies show that reduction of SERCA2a in failing ventricle is a key factor in depression of contraction, and that restoration of SERCA2a levels can improve left ventricular function and remodeling.
The aim of the study is to investigate the effect of an adeno-associated viral vector expressing the sarcoplasmic reticulum calcium ATPase (SERCA2a), driven by the CMV promoter (AAV1-CMV-SERCA2a), on the ventricular remodeling of patients with severe heart failure using multimodality cardiac imaging.
This is a Phase 2 monocenter double blind randomized placebo-controled, parallel study. The study will enroll 44 symptomatic heart failure patients with NYHA IIIb/IV, with left-ventricular ejection fraction of 35& or less receiving an optimal standard medical therapy.
The absence of neutralizing antibodies against AAV1 will be primarily checked. Seronegative patients will be randomized to receive either 1x10e13 AAV1-CMV-Serca2a or a placebo as a single intracoronary infusion. Evolution during the next 6 months of the left ventricular end-systolic volume (measured with a 256-slices CT-scan before injection and 6 months later) will be the primary endpoint. Secondary endpoints will include changes in the LVEF, diastolic volumes, VO2max, Echocardiographic remodeling, BNP, cardiac hemodynamics and biological safety profile.

source clinicaltrials.gov

Publication

  • Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure : results from the AGENT-HF randomized phase 2 trial
    Jean-Sébastien Hulot, Joe-Elie Salem, Alban Redheuil, Jean-Philippe Collet, Shaida Varnous, Patrick Jourdain, Damien Logeart , Estelle Gandjbakhch, Claude Bernard, Stéphane N Hatem, Richard Isnard, Philippe Cluzel, Claude Le Feuvre, Pascal Leprince, Nadjib Hammoudi, François M Lemoine, David Klatzmann, Eric Vicaut, Michel Komajda, Gilles Montalescot, Anne-Marie Lompré, Roger J Hajjar, AGENT-HF Investigators
    Publicated in European Journal of Heart Failure

Autres études

+

ANCHOR

En cours


Demonstrate the superiority of an association of VA-ECMO and IABP with an optimal medical treatment compared with an optimal medical treatment only in cardiogenic shock AMI patients
+

EDUC-DAI

En cours


Impact of therapeutic education on the quality of life and the anxiety of patients with a defibrillator.
+

AMUNDSEN

En cours


A phase IV, multicentric, randomized, real-world pragmatic study that compares a strategy of early LDL reduction with anti-PCSK9 in patients defined as extreme high risk by 2019 ESC/EAS guidelines vs....